A new tablet, orforglipron, helped people with type 2 diabetes lose more weight than oral semaglutide.
Participants lost up to 8% of their body weight within one year.
The drug lowers blood sugar, slows digestion, and reduces appetite.
Patients can take it without fasting, which simplifies daily use.
Researchers studied more than 1,500 adults across several countries.
Orforglipron improved blood sugar control more than the comparison treatment.
More patients stopped the drug because of stomach-related side effects.
Regulators have not yet approved the medication.
Experts see strong potential for easier, cheaper treatment.
Long-term safety and cardiovascular effects still require further study.
